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Background: Cancer of unknown or uncertain primary is a major diagnostic and clinical challenge, since identifying
the tissue-of-origin of metastases is crucial for selecting optimal treatment. MicroRNAs are a family of non-coding,
regulatory RNA molecules that are tissue-specific, with a great potential to be excellent biomarkers.
Methods: In this study we tested the performance of a microRNA-based assay in formalin-fixed paraffin-embedded
samples from 84 CUP patients.
Results: The microRNA based assay agreed with the clinical diagnosis at presentation in 70% of patients; it agreed with
the clinical diagnosis obtained after patient management, taking into account response and outcome data, in 89% of
patients; it agreed with the final clinical diagnosis reached with supplemental immunohistochemical stains in 92% of
patients, indicating a 22% improvement in agreement from diagnosis at presentation to the final clinical diagnosis. In 18
patients the assay disagreed with the presentation diagnosis and was in agreement with the final clinical diagnosis, which
may have resulted in the administration of more effective chemotherapy. In three out of four discordant cases in which
supplemental IHC was performed, the IHC results validated the assay’s molecular diagnosis.
Conclusions: This novel microRNA-based assay shows high accuracy in identifying the final clinical diagnosis in a real life
CUP patient cohort and could be a useful tool to facilitate administration of optimal therapy.
Keywords: MicroRNA, Carcinoma of Unknown Primary (CUP), Tumor-of-origin, Molecular diagnosticsBackground
Cancer of unknown primary (CUP) is defined as the
presence of histologically verified metastases without a
clinically detectable primary tumor. CUP constitutes 3%-5%
of all newly diagnosed cancer cases, and if cancer of uncer-
tain origin is added, the total number increases to 12-15%.
Both CUP and cancer of uncertain origin present a diag-
nostic as well as a management challenge to clinicians. The* Correspondence: yael_sp@rosettagenomics.com
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distribution, and reproduction in any mediumidentification of tumor origin in metastatic patients is cru-
cial for planning patient management and care since many
oncologic treatments include targeted therapies shown to
be effective against specific cancers [1-5]. Moreover tumor-
specific therapies lead to increased survival of patients with
advanced cancers of known origin [5,6].
Identifying the origin of a metastasis is a complex diag-
nostic process that includes patient history and physical
examination, computerized tomography of chest and
abdominopelvic cavity supplemented by sign/symptom-
directed imaging/endoscopic work-up, histomorphologic
assessment of the tumor and immunohistochemistryCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Diagnostic process and agreement to the 64
microRNA assay. At the time of referral, each patient was assigned
the most likely clinical diagnosis based on all data available at
presentation (“Presentation Clinical Diagnosis”). Later on based on
additional data gathered during treatment and follow up, each
patient was assigned one to three sites of origin (“Clinical
Diagnosis”). Finally we performed more IHC tests and arrived at a
final diagnosis (“Final Clinical Diagnosis”). For all patients, we
independently performed the 64 microRNA assay (assay Results) and
compared these to the clinical work-up. The number on each arrow
depicts the number of patients (out of 84) for which there was
agreement between the test results and the clinical diagnosis, and
the number in parenthesis depicts this agreement in percentage.
See Methods for more details.
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markers and development of stepwise algorithms have
improved IHC accuracy to 60-88%, they are relatively
subjective and fail to determine a single tissue of origin in
20-40% of cases [7-9]. Therefore, molecular diagnostic
tools have become an important necessary addition, espe-
cially for helping to resolve cases of uncertain primary. Cur-
rently, assays for molecular profiling of cancers of
unknown primary are available using microarrays and
quantitative real-time PCR, for messenger RNA (mRNA)
[10-12] or microRNA [13] expression. MicroRNAs are par-
ticularly suitable as biomarkers for identifying tumor origin
as their expression levels and profile reflect tissue origin
and tumorigenesis [14-17]. Moreover, microRNAs have
been shown to be highly stable in formalin-fixed paraffin-
embedded (FFPE) tissue blocks, the most common and
readily available specimen type in pathology [18-20]. Profil-
ing microRNA from FFPE tissue has been described to be
superior to mRNA profiling, since the latter are prone to
extensive degradation in FFPE samples [20,21].
We have recently described the development and
validation of a second generation array-based assay, the
64 microRNA assay (Rosetta Cancer Origin Test™), that
identifies 42 tumor types from FFPE tumor samples
based on the expression levels of 64 microRNAs [13].
This assay is a significant improvement to the previous
first-generation qRT-PCR based assay that identified 25
tumor types using 48 microRNAs. The current novel
assay is designed to identify tissue of origin of both
metastases and primary tumors from biopsy/resection.
The assay was validated using an independent cohort of
509 samples of known origin metastases [13].
Earlier studies validating molecular assays for tissue
of origin diagnosis used samples from known origins
[11,12,17,22,23]. More recently, a number of studies have
been performed assessing molecular assays in the relevant
clinical setting of real CUP patients [13,24-29]. Here we
present the performance of the 64 microRNA assay in a
blinded study on a well annotated cohort of real CUP
patients presenting metastases in multiple sites and from
multiple origins. In this setting of CUP we compare the
assay results with the suspected diagnoses of the patients
from initial presentation throughout treatment and follow
up. We demonstrate the clinical relevance for management
decisions following use of the assay.
Results
In this study, 93 samples from 92 CUP patients were
tested blindly with the 64 microRNA assay. Eight sam-
ples failed processing due to inadequate RNA quality. 85
samples from 84 patients were processed successfully
(91%) and were assigned assay results. For one patient
(12399), two biopsies were made from two different me-
tastasis sites. The two samples yielded the same assayresult and hence we report here on 84 results. For each
of these 84 patients we obtained both a full clinicopatho-
logic work-up and the result of the 64 microRNA assay.
Figure 1 describes the diagnostic process and the agree-
ment with the 64 microRNA assay results. Interestingly,
the concordance between the microRNA assay and the
clinical diagnosis increased with the progress in clinical
work-up, from 70% concordance with the presentation
clinical diagnosis to agreement of 89% with the clinical
diagnosis during patient management, finally reaching
92% agreement with the final clinical diagnosis, which
involved additional IHC studies in four cases (Figure 1).
For these concordance studies, the molecular diagnosis
took into account the two possible predictions. Thus,
the assay results which were obtained based on the ini-
tial biopsy/resection were shown to be predictive of the
final clinical diagnosis.
For 9 patients (11%), the assay results were discordant
with the clinical diagnosis (Figure 1). We selected 7 of
those cases for re-evaluation by additional IHC to deter-
mine whether the assay may in fact have pointed to an
origin missed in the clinical work-up. In addition we se-
lected a case where the assay reported two possible ori-
gins, with the second one being concordant with the
clinical diagnosis. Sufficient material for re-testing was
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12432, 12412, and 11826). Based on the 64 microRNA
assay results for these 4 cases, specific IHC markers
were chosen and used for IHC staining in order to sup-
port or refute the assay results. In 3 out of the 4 re-
tested samples, additional IHC work-up resulted in
agreement with the 64 microRNA assay results (or in a
shift from agreement with the second assay call to agree-
ment with the first assay call). See Table 1 for the de-
scription of these 4 cases and the results of the new
IHC. In the last part of the results we focus in detail on
two of those cases to exemplify the added benefit the 64
microRNA assay may have on patient diagnosis and sur-
vival. Following the results of the new IHC performed,
the final clinical diagnosis of 3 patients was changed and
the concordance of the microRNA-based assay with the
final clinical diagnosis reached 92%.
Table 2 summarizes the statistics of agreement be-
tween the final clinical diagnoses and the 64 microRNA
assay result, which is either a single origin or two ori-
gins. The analysis divides the patients into four groups;
1) Patients for whom the assay agreed with the final
clinical Diagnosis but not with the presentation
clinical Diagnosis (21.5%).
2) Patients for whom the assay reported one result that
agrees with both the presentation clinical Diagnosis
and the final clinical Diagnosis (39.5%),
3) Patients for whom the assay reported two results, at
least one of which agrees with both the presentation
clinical Diagnosis and the final clinical Diagnosis (31%).
4) Patients for whom the assay results did not agree
with the final clinical Diagnosis (8%).
It is important to note that from the 33 patients in the
cohort that received two assay answers (group 3), onlyTable 1 Immunohistochemical results for 4 cases
Patient id Original IHC results New IHC results
12432
CK7(+), CK8(+), CK19(+),






CK 7(+), CK20(-), CA125(+), ER(-), PR(
CEA(-), p63(-)
11826 none performed
CK7 (+), ER(-), PR(-),GCDFP15(-), S-100
(rare cells with only weak cytoplasm
immunoreactivity, therefore this stain





TTF1(+), CK7(+, focally), CK20(-),
CHROMOGRANIN(+), SYNAPTOPHYSIN
CK13(-), CK14(-), CD56(+)three patients had their concordant results from the sec-
ond answer, whereas for 28 patients the agreement was
with the first (most probable) answer.
The first group (18 patients) includes patients who
would have benefited the most from access to the 64
microRNA assay result, since the assay in those cases
was not in agreement with the presentation clinical diag-
nosis and was in agreement with at least one of the final
clinical diagnoses.
Case report 1 – patient id # 12432
A 61-year-old female patient, suffering from peritoneal
carcinomatosis and ascites, underwent laparoscopic ad-
nexal, ovarian and peritoneal biopsies and was diagnosed
with CUP. Ovaries were normal, but the adnexal biopsy
disclosed an adenocarcinoma positive for CK7, CK8,
CK19, CA125, and PR and negative for CK20, CEA,
TTF1, CA19-9 and vimentin. Initial clinical and patho-
logical information suggested a diagnosis of primary
peritoneal or ovarian carcinoma. Throughout her care, a
potential diagnosis of endometrial cancer was added in
the differential diagnosis. The patient did not respond to
first line taxane-platinum therapy as anticipated but
exhibited a rather indolent disease course, reaching
an overall survival of 30 months on 2nd line oral
vinorelbine, followed by best supportive care only. The
64 microRNA assay provided a single answer of pleural
mesothelioma. Since this result did not agree with the
presentation clinical diagnosis, nor did it agree with the
clinical diagnoses, additional IHC tests were performed
(CK5/6, mesothelin, calretinin, EMA, and LEUM1, see
Table 1, Figure 2). Pathologic review of the additional
IHC stains agreed with the diagnosis of mesothelioma,
although it was still debated whether it was pleural or
peritoneal (the 64 microRNA does not differentiate be-
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Table 2 Differential diagnosis of patients
Patient
group #




Dx & microRNA test
agreement
Final clinical Dx &
microRNA test 1st
result agreement
Final clinical Dx &
microRNA test 2nd
result agreement
1 microRNA-based results agree with Final
Clinical Dx but not with Presentation
Clinical Dx
18 (21.5) 3/18 0/18 16/18 2/18
2 microRNA-based test reported a single
result which agreed with Final Clinical
Dx and with Presentation Clinical Dx
33 (39.5) 22/33 33/33 33/33 0/33
3 microRNA-based test reported two results
which agreed with Final Clinical Dx and
with Presentation Clinical Dx
26 (31) 13/26 26/26 25/26 1/26
4 microRNA-based results are not
consistent with Clinical Dx
7 (8) 0/7 0/7 0/7 0/7
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from platinum/taxane to pemetrexed/platinum salts,
which could have resulted in improved survival.
Case report 2 - patient id # 11805
A 60-year-old male presented with a pelvic soft tissue
mass, subcutaneous deposits, lung and bony metastases
without any evidence of a primary tumor. A subcutane-
ous deposit was biopsied, disclosing an adenocarcinoma
positive for cytokeratins and negative for vimentin. The
patient was managed with oxaliplatin + irinotecan for
4 months in the context of a CUP clinical trial, failed
to respond and subsequently received paclitaxel/car-
boplatin combination chemotherapy. This resulted in
partial remission of the malignancy and an overall
survival of 20 months. The final clinical diagnoses were
either lung adenocarcinoma or pancreatic adenocarcin-
oma. In contrast, the 64 microRNA assay suggested
small cell lung carcinoma as the first result, and large
cell or adenocarcinoma of the lung as the second result.
The biopsied tissue was then analyzed with another
microRNA based assay, Rosetta Lung Cancer Test™ [30]
and the result supported the first assay answer (the
higher confidence result) of small cell lung carcinoma.
Additional IHC work up on the archived bioptic material
(TTF1, CK7, CK20, chromogranin, synaptophysin, and
CD56, see Table 1, Figure 3) resulted in a diagnosis thatFigure 2 IHC results for patient # 12432 (Case report 1). Results
of further IHC performed for patient #12432 following the 64
microRNA assay results: A Calretinin X400, B Mesothelin X400was in agreement with the 64 microRNA assay first
answer of small cell lung carcinoma. This knowledge
could have prevented the administration of ineffective
oxaliplatin/irinotecan therapy to the patient, and could
have resulted in the administration of platinum-based
regimens earlier during the course of the disease.
Discussion
MicroRNAs have been repeatedly shown to be sensitive
diagnostic markers to identify tissue of origin [13,17,31].
This potential for tissue of origin identification is evident
since microRNAs bear an important role in protein ex-
pression regulation and therefore their expression in
cells depends on their origin and type.
The importance of correct and rapid diagnosis in CUP
patients is critical since the origin of the malignancy dic-
tates the optimal therapeutic treatment for the patient,
which could have a positive impact on patient outcomes.
Standard diagnosis of CUP patients is based on patho-
logical evaluation supplemented by IHC tests, patient’s
history, clinical presentation and relevant imaging tests
coupled to serum tumor markers. Nevertheless, the clin-
ician quite often changes the diagnosis of the suspected
tissue of origin or additional suspected origins are added
to the differential diagnosis, due to the course of the dis-
ease, response to therapy and outcome.Figure 3 IHC results for patient # 11805 (Case report 2). Results
of further IHC performed for patient #11805 following the 64
microRNA assay results: A Chromogranin X100, B
Synaptophysin X100
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to determine the most appropriate stains to use, any
additional objective data should help physicians to ra-
tionalize the diagnostic algorithm. Therefore, molecular
diagnostics are high-value clinical tools that can provide
key answers to both pathologists and oncologists.
Both mRNA and microRNA expression have been
used to develop specific assays and algorithms to deter-
mine the tissue of origin in patient samples. MicroRNAs
have been shown to be superior to mRNA when using
FFPE samples, the routine preservation method for
histological evaluation of biopsies and resections.
MicroRNAs are more stable than mRNA in FFPE blocks
and microRNA extracted from FFPE blocks show similar
profiles to microRNA extracted from fresh tissue [17].
An array-based assay utilizing microRNAs (Rosetta
Cancer Origin Test™) was therefore developed and vali-
dated. The assay is capable of identifying 42 different
tumor types using a set of 64 microRNAs. The assay al-
gorithms (KNN classifier and decision tree) were trained
using a total of 1282 primary and metastatic samples
from known origins. The assay returns either a single
tissue of origin or two possible origins. Validation of this
64 microRNA assay on an independent set of 509 sam-
ples, from known origins, demonstrated a high level of
accuracy; sensitivity for a single answer prediction of
90%, overall sensitivity of 85% and overall specificity of
up to 99% [13]. A separate validation study on 52 true
CUP cases of CNS origin demonstrated 88% concord-
ance with clinical presentation and pathology [13].
In this study we tested a cohort of real CUP patients
presenting metastases in various sites using the 64-
microRNA assay, which demonstrated agreement with
pathological and clinical information that increased with
the clinical course of the patient. In the absence of a
clear gold standard diagnosis in true CUP cases it is
challenging to assess the agreement between the mo-
lecular assay’s results and the clinical diagnosis. The
suspected final clinical diagnosis is based on clinicopath-
ologic data, the patient course, response to tissue-
specific therapies and survival, and additional IHC tests
when needed. The suspected tissue of origin may be
revised with time as more data is gathered during
patient’s management. The diagnosis based on the
clinical and pathological data available at presentation,
and without additional data gathered throughout patient
management, had only 70% agreement with the assay re-
sults. The agreement with the final clinical diagnosis was
92%. Thus, for about 22% of the patients the microRNA
assay would have suggested a relevant differential diag-
nosis that was not considered at presentation and was
later considered as one of the final clinical diagnoses
gathered throughout patient care. Moreover, in a few
cases the 64-microRNA assay triggered the use ofadditional IHC stains (to test for candidate origins that
were not suspected as likely during patient’s diagnosis
and treatment), which either validated the molecular
diagnosis or contributed to further analysis and correc-
tion of the final diagnosis.
Recently, a similar study was published on real CUP pa-
tients using an mRNA-based test reaching only 74-77%
agreement with clinical and pathological information in-
cluding IHC, some of which were triggered by the assay re-
sults [25].
In order to correctly evaluate the clinical significance
of the 64-microRNA assay, we studied specific cases
where the added information given to the clinician
would have contributed to a revised diagnosis and to a
modification of therapy. In fact, for the 18 patients for
whom the molecular assay would have resulted in a revi-
sion of the presentation clinical diagnosis, different
chemotherapy may have been administered in all 18 pa-
tients, and the revised therapy would probably have been
more active and associated with increased survival in
nine patients. Finally, the change in diagnosis would
have probably resulted in modification of expensive,
targeted therapies in 16 out of 18 patients.
There is controversy whether CUP patients fare bet-
ter when treated with primary-specific therapy rather
than with empiric combination chemotherapy. A re-
cent paper studied CUP patients who received assay-
directed site-specific treatment [32]. The results of
this research suggest that the survival of patients
treated with assay- directed therapy is better than the
expected survival for CUP patients described in the
literature. Additional studies are required in order to
validate these findings.
A clinically challenging question is how to handle
cases in which the clinicopathologic and molecular diag-
noses disagree. Our stepwise study of molecular diagno-
sis agreement with the clinical diagnosis at presentation
and with the final clinical diagnosis at the conclusion of
patient management strongly suggests that the molecu-
lar diagnosis is a very powerful tool for correctly identi-
fying the primary.
We therefore conclude that microRNA profiling is in-
deed a useful adjunct to traditional clinical and patho-
logic evaluation for CUP cases, when the sample
processing yielded a test result. The assay can help by
narrowing down the potential diagnostic options and by
increasing confidence in a suspected tissue of origin
diagnosis, or by suggesting a different origin resulting in
more timely administration of optimal therapy.
Methods
Patients and sample preparation
93 FFPE CUP blocks were collected retrospectively from 92
patients diagnosed with CUP according to a standardized
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Hellenic Cooperative Oncology Group (HeCOG) - affiliated
centers from 2001 until 2009. Most patients were males
(59), and belonged to visceral (29), squamous head neck
(18), midline nodal (10), peritoneal carcinomatosis (18) and
axillary nodal (9) CUP subgroups. H&E sections and IHC
workup from all cases were reviewed centrally by an inde-
pendent pathologist (AG). Optimal IHC work up was avail-
able in 64 cases (median of 8 IHC stains, range 4–12).
Eighty five samples from 84 patients are the subjects
of this study as 8 samples had inadequate RNA quality
and did not pass the assay’s QA criteria. See Table 3 for
patient information. These 84 patients were assigned
three diagnoses over time:
1) At the time of referral each patient was assigned the
most likely clinical diagnosis based on all data available
at presentation (signs, symptoms, metastatic sites, dis-
ease bulk, patient’s history, pathological evaluation in-
cluding IHC testing). We called this “presentation
clinical diagnosis”.Table 3 Patient information
N= 84 N
Median age
(interquartile range) 65 (53 – 70)
Gender Male 45
Female 39













Peritoneal carcinomatosis 18 (15/3)
(Serous/Mucinous)
Midline nodal 10
Squamous cervical nodal 18
Chemotherapy Chemo (Yes / No) 63/ 21
Platinum-based 27
Platinum + Taxane 23
Taxane-based 3
Other 10
Median PFS (95% CI) 7 months (4.8 – 9.2)
Median OS (95% CI) 12 months (8.7 – 15.3)2) Later on during the course of the disease each pa-
tient was assigned one to three sites of origin. We called
these “clinical diagnosis”, as for reaching these “clinical
diagnoses” we took into account additional data gath-
ered during treatment and follow up, such as response
to therapies, spatial and temporal pattern of relapse, and
survival.
3) Following the molecular diagnosis provided by the
64 microRNA assay, supplemental IHC tests resulted in
the “final clinical diagnosis”.
The clinical team and the team performing the assay
were blinded to each other regarding the first two diag-
noses, and the molecular diagnosis provided by the 64
microRNA assay. Un-blinding was performed only at the
time of data analysis to examine agreement between
clinical and molecular diagnoses and in order to perform
supplemental IHC tests.
The 64 microRNA assay procedure
The assay was performed on FFPE tissue, and H&E
slides were reviewed by a surgical pathologist for suit-
ability regarding tumor cell content, surrounding tissue,
amount of necrosis, inflammation, hemorrhage, and
fibrosis. The method has been validated for a tumor
cell content of at least 50%. When feasible, micro-
dissection was performed to increase the tumor cell
content to beyond 50% on the basis of tumor size and
histologic features. Suitable samples were processed as
previously described [13] to generate tissue of origin
results. Briefly, total RNA is extracted by using acid
phenol–chloroform extraction, and RNA is labeled by
ligation of an RNA-linker, p-rCrU-Cy/dye and quanti-
fied using custom-designed arrays from Agilent
Technologies. Arrays are scanned, and the signal values
of 64 assay microRNAs are obtained following
normalization, and used as input to the assay’s classi-
fiers. Inadequate RNA quality is defined either as insuf-
ficient amount of RNA to run the assay (less than
0.25ug) or, for example, an RNA sample that resulted
with less than 65 microRNAs having a signal of at least
500 on the array.
The assay relies on two classifiers to determine the
tissue of origin; a K nearest-neighbor (KNN) classifier
and a binary decision tree. Each of the two classifiers
predicts one of the 42 tumor types or one of seven com-
bined tumor classes (e.g. Adenocarcinoma of Biliary
Tract or Pancreas), and assigns a confidence measure to
its prediction. The two predictions are then combined
into a single predicted tissue origin or two different pre-
dictions, based on whether the two classifiers agree, and
on their confidence measures. When two predictions are
reported, they are ranked by the Positive Predictive
Value (PPV) of each answer. When both classifiers
exhibit very low confidence in their result, the assay does
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expression pattern of the sample does not match any of
the expression patterns in the panel closely enough,
which happens in ~2% of cases, and did not happen for
any of the cases in this study. See Meiri et. al. for more
details on the assay [13].
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